Human Health

read it

Novel immunotherapeutic treatment for superficial Bladder Cancer

IP Status: PCT Application filed on July 2013

Description: Bladder cancer is the 4th most common cancer in men in industrialized countries. Most of them are treated using the citotoxic activity of BCG (Mycobacterium bovis). Nevertheless, such treatment is not as safe as desirable, provoking many side effects (some of them serious). BCG is included in a biosafety level of 2. We have developed an alternative treatment using other Mycobacterium obtaining similar results as achieved with BCG or even better in vitro and in vivo. The main advantage is that our Mycobacterium is not hazardous and has a growth rate that allows a feasible industrial production.

Department: Department of Genetics and Microbiology

Contact: Lucas Martín

Modified siRNAs for silencing TNF- gene expression to treat inflammatory diseases  

read it

IP Status: Spanish application filed

Description: CSIC, the Universitat de Barcelona and the Universitat Autónoma de Barcelona have developed new small interfering RNAs (siRNA) chemically modified for treatment of inflammatory diseases, particularly intestinal diseases, through TNF-? gene expression silencing. These compounds show high inhibitory activity and reduce the non-specific immune response triggered by other synthetic siRNAs.

Department: Department of Cell Biology, Physiology and Immunology

Contact: Lucas Martín

read it

Protein nanoparticles for the targeted therapy of aggressive tumours and metastasis

IP Status: Priority 2011

Description: We have developed a new drug delivery system for the selective treatment of metastasis based on peptide nanoparticles that lead therapeutic agent to tumoral cells and allow the internalization of the therapeutic material. This specificity is achieved because our nanocarrier only binds to the receptor CXCR4 (overexpression of CXCR4 correlates with agressive tumors and metastasis progression). Our technology provides for the first time a highly targeted drug delivery system for the treatment of metastasis (by targeting the cancer stem cells). Our peptide nanoparticles can target tumoral cells very specifically, allowing a delivery of a wide range of therapeutic agents (peptides, siRNA, etc.) and permitting a treatment with a precise adjustement of the dosage regimen. Currently we are testing the performance of the nanoparticle covalently bound to a very strong antimitotic toxin.

Department: Department of Genetics and Microbiology

Contact: Lucas Martín

Apotransferrin to treat stroke 

read it

IP Status: PCT/EP2012/072195

Description: Intravenous administration of apotransferrin reduces brain damage caused by ischemic stroke (up to 75%) and also improves neurological impairment induced by stroke. Apotransferrin can be administered at the same time asa thrombolytic agent and/or during surgical intervention to remove the thrombus.We are seeking a company partner to commercialize this licensing opportunity.

Department: Department of Cell Biology, Physiology and Immunology & Department of Neurology Institute Germans Trias i Pujol

Contact: Maite Ibern

read it

Optopharmacological compounds targeting mGlu5 receptors

IP Status: Priority patent application filed

Description: CSIC, IBEC, UAB and CNRS have developed the first light-regulated mGluR5 negative allosteric modulators. Control of drug action is obtained by means of light irradiation, being these drugs capable of reversible switching between inactive and active states for controlled application in treatment of pain or Parkinson among other diseases.

Department: Department of Pediatrics, Obstetrics and Gynecology and Preventive Medicine

Contact: Lucas Martín

New lipidic compositions for coating bacteriophages  

read it

IP Status: European Patent Application filed on February 2014

Description: Bacteriophages for control of bacteria are widely used and exist several commercial products already to be used as surface disinfectants, livestock bacterial control agent or food safety product. The problem is that often such products do not show an optimal performance due to different causes: - pH: If naked bacteriophages are administered to animals or humans a significant decrease of the effective concentration is observed due to the low pH condictions of the gastrointestinal tract. - Storage: Liophylization is a good solution for product storage. Nevertheless, when bacteriophages are liophylized an important decrease of the infectivity is observed. The nanoparticles developed by our scientists allow a great viral performance of the phages even if they are administered to animals or if they have been liophylized. Experimental data in Salmonella contaminated poultry show that coated bacteriophages have the same lytic activity than naked bacteriophages but show longer efficcacy against bacteria.

Department: Department of Genetics and Microbiology

Contact: Lucas Martín

read it

 A new method for treating parasitic diseases using dichloroacetate

IP Status: European Patent Application filed in 2014

Description: The inventors found that glycolytic parasites —those basing ATP production and biomass generation mainly on aerobic fermentation, including Leishmania spp., Toxoplasma spp., Plasmodium spp. or Trypanosoma spp.—, can be inhibited by blocking the glycolytic pathway with dichloroacetate (DCA), thus providing a new method for treating parasitic diseases caused by these parasites.

Department: Department of Pharmacology, Therapy and Toxicology, Veterinary Faculty UAB

Contacte: Lucas Martín

New high-throughput method to genotype human inversions for personalized medicine purposes  

read it

IP Status: Priority European patent application, 23rd July 2013

Description: Novel high-throughput assay to genotype those human inversions in human genome that can not be detected by current techniques. Human inversions have a role in phenotypic characteristics, including susceptibility to genetic diseases and genomic disorders however they cannot  be detected by massive sequencing techniques. This method provides key information highly useful in the field of personalized medicine (diagnostic, genetic test, drug development and clinical trials). We are seeking a company partner to commercialize this licensing opportunity

Department: IBB (Institute of Biotechnology and Biomedicine)

Contact: Maite Ibern
 

read it

New single-chain variable fragment as a drug to treat Alzheimer's disease

IP Status: PCT application, 16th May 2014

Description: At present, there is no cure for Alzheimer’s disease and 44 M  people suffer from it. By 2030, this figure will increase to 76 M  and by 2050 could exceed 135 M people. New elongated Single-Chain Variable Fragments (scFv) of the antibody Bapineuzumab developed by UAB scientific team show their efficiency for Alzheimer’s disease (AD) treatment at low dosage avoiding adverse side effects. We are seeking a company partner to commercialize this licensing opportunity.

Department: Biochemistry and Molecular Biology, Biosciences unit

Contacte: Maite Ibern
 

New isolated Bacterial Strains available to study pharma and food indications 

read it

Description: Bacterial strains from a natural source have been isolated and characterized by researchers at the Universitat Autònoma de Barcelona. These belong to genera listed below: Torulaspora, Kazachstania, Issatchenkia, Saccharomyces, Kluyveromyces, Pichia, Lactobacillus, Rhodotorula, Aerococcus, Pediococcus, Enterococcus, Weissella, Exophiala, Trichosporon, Lactococcus and Streptococcus.
 
Protection: Know-how
 
We offer access to the bacterial strains to pharma, biotech and food industry under licensing agreement (exclusive or non-exclusive).


Department: Faculty of Veterinary

Contact: Maite Ibern